share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Mar 27 06:29
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司於2024年3月11日至27日進行了一系列的股份回購活動，共回購了數百萬股A股普通股，但並未註銷這些股份。根據香港聯合交易所有限公司證券上市規則，公司需披露已發行股本的變動。在這段期間，公司的股份回購價格與市場價格相比，有時出現溢價，有時則為折讓。此外，公司於2024年3月27日根據2019年A股激勵計劃行使股票期權，並發行了1,300股A股普通股。公司確認，所有相關的股份發行均已獲得董事會的正式授權和批准，並且已符合所有適用的上市規則和法律要求。
無錫藥明康德新藥開發股份有限公司於2024年3月11日至27日進行了一系列的股份回購活動，共回購了數百萬股A股普通股，但並未註銷這些股份。根據香港聯合交易所有限公司證券上市規則，公司需披露已發行股本的變動。在這段期間，公司的股份回購價格與市場價格相比，有時出現溢價，有時則為折讓。此外，公司於2024年3月27日根據2019年A股激勵計劃行使股票期權，並發行了1,300股A股普通股。公司確認，所有相關的股份發行均已獲得董事會的正式授權和批准，並且已符合所有適用的上市規則和法律要求。
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted a series of share repurchases from 11 to 27 March 2024, which repurchased millions of shares of A common shares, but did not write them off. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose changes in issued share capital. During this period, the company's share repurchase price is sometimes at a premium compared to the market price and sometimes a discount. In addition, the Company exercised stock options under the 2019 A-share incentive plan on March 27, 2024 and issued 1,300 shares of A-shares ordinary shares. The Company confirms that all relevant share issues have been formally authorized and approved by the Board of Directors and have complied with all applicable listing rules and legal requirements.
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted a series of share repurchases from 11 to 27 March 2024, which repurchased millions of shares of A common shares, but did not write them off. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose changes in issued share capital. During this period, the company's share repurchase price is sometimes at a premium compared to the market price and sometimes a discount. In addition, the Company exercised stock options under the 2019 A-share incentive plan on March 27, 2024 and issued 1,300 shares of A-shares ordinary shares. The Company confirms that all relevant share issues have been formally authorized and approved by the Board of Directors and have complied with all applicable listing rules and legal requirements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more